March 1st Week, 2026 Regulatory Events 🎯 The European Commission approved Incyte’s retifanlimab (anti-PD-1) + carboplatin + paclitaxel for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal. (Ref 1) ❓ How do the outcomes of this regimen compare against the current SOC? 🎯 The US FDA approved Johnson & Johnson Innovative Medicine’s teclistamab (BCMA-directed CD3 T-cell engager) + daratumuma